Prime assembly, a novel genome engineering method leveraging CRISPR-targeted dual flap synthesis, allows long DNA fragments to be integrated into precise and programmable target positions within living cells, according to a paper published in Nature. Developed to overcome the limitations of untargeted gene delivery and short DNA edits that require individualization for each patient, the technique may enable the development of universal gene therapies.
How Prime Assembly Integrates Long DNA Fragments
The method builds upon prime editing, a technology that traditionally permits precise yet small insertions, deletions, and base swaps. According to the study authors, prime assembly enables RNA-programmable site-specific integration of single- or double-stranded DNA fragments. Unlike homology-directed repair, the new approach remains similarly active in both dividing and non-dividing cells.
Prime assembly operates via a single-step process that writes new DNA flaps into specific genomic locations. These flaps serve as tethers designed to grab onto DNA fragments with matching ends. The precisely assembled DNA inserts—spanning one or more gene-sized pieces—become large permanent edits.
“By using prime editing to write in one flap per strand of the genome, the method controls exactly where the DNA replacement starts and ends,” explained Daniel Bauer, MD, PhD, director of the Gene Therapy Program at Boston Children’s Hospital. “Because the method is based on prime editing, it is much less likely to cause off-target effects compared to other gene editing methods.”
Pro Tip: Unlike traditional methods mostly limited to dividing cells, prime assembly functions effectively in non-dividing cells, expanding the scope of targetable tissues.
Safety Advantages Over Traditional Gene Editing
Untargeted insertion methods carry the risk of turning on the wrong genes in the wrong context, potentially leading to cancerous outcomes. Prime assembly’s targeted insertion approach circumvents this risk.
Furthermore, the technique does not rely on DNA double-strand breaks or DNA double-strand donors. Both breaks and donors can be toxic and induce unwanted cell stress. By avoiding these mechanisms, prime assembly reduces potential toxicity in primary human cells.
Did you know? Prime assembly was successfully applied by the research team to perform targeted exon recoding, transgene integration, and megabase-scale rearrangements at therapeutically relevant loci in primary human cells.
Clinical Applications and Next Steps for In Vivo Delivery
The research team is currently investigating molecular mechanisms to engineer even more efficient and precise systems. By fine-tuning this approach, investigators hope to achieve downstream clinical impact for patients with genetic disorders.
“We’re working to improve the delivery of the prime assembly components to disease-relevant human cells in vivo, such as hematopoietic stem cells for blood disorder therapies,” said Bauer. “We’re also exploring a number of applications of prime assembly to deliver genetic payloads as mutation-agnostic therapies to restore gene control for devastating inherited human diseases with unmet clinical need.”
Frequently Asked Questions
What is prime assembly?
Prime assembly is a novel genome engineering method based on prime editing that allows the integration of long DNA fragments into precise, programmable target positions within living cells using CRISPR-targeted dual flap synthesis.
How does prime assembly differ from standard gene editing?
Unlike methods that rely on DNA double-strand breaks or homology-directed repair, prime assembly writes in DNA flaps to tether matching fragments without causing double-strand breaks, and it works efficiently in both dividing and non-dividing cells.
What are the potential clinical uses of this technology?
Researchers are investigating prime assembly for targeted exon recoding, transgene integration, megabase-scale rearrangements, and mutation-agnostic therapies for inherited blood disorders and other genetic diseases.
Explore More: Stay updated on the latest breakthroughs in biotechnology and gene therapy by subscribing to our newsletter or exploring our archives for more peer-reviewed research breakdowns.